Compliance therapy for schizophrenia

Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of people given these drugs do not comply with the treatment regimen prescribed. To assess the effects of compliance therapy on antipsychotic medi...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews no. 3; p. CD003442
Main Authors: McIntosh, A M, Conlon, L, Lawrie, S M, Stanfield, A C
Format: Journal Article
Language:English
Published: England 19-07-2006
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of people given these drugs do not comply with the treatment regimen prescribed. To assess the effects of compliance therapy on antipsychotic medication adherence for people with schizophrenia. Cochrane Schizophrenia Group Trials Register (June 2005). We included all randomised controlled trials of 'compliance therapy' for people with schizophrenia or related severe mental disorders. We independently extracted data and, for dichotomous data, calculated the relative risk (RR), its 95% confidence interval (CI) on an intention to treat basis. We present continuous data using the weighted mean difference statistic. We included one trial with relevant and available data (n=56, duration 2 years) comparing compliance therapy with non-specific counseling. The primary outcome 'non-compliance with treatment' showed no significant difference between compliance therapy and non-specific counseling (n=56, RR 1.23 CI 0.74 to 2.05). The compliance therapy did not substantially effect attitudes to treatment (n=50, WMD DAI score -2.10 CI -6.11 to 1.91). Very few people (~10%) left the study by one year (n=56, RR 0.5 CI 0.1 to 2.51). Mental state seemed unaffected by the therapy (n=50, WMD PANSS score 6.1 CI -4.54 to 16.74) as was insight (n=50, WMD SAI -0.5 CI -2.43 to 1.43), global functioning (n=50, WMD GAF -4.20 CI -16.42 to 8.02) and quality of life (n=50, WMD QLS -3.40 CI -16.25 to 9.45). At both one and two years the average number of days in hospital was non-significantly reduced for those allocated to the compliance therapy. There is no clear evidence to suggest that compliance therapy is beneficial for people with schizophrenia and related syndromes but more randomised studies are justified and needed in order for this intervention to be fully examined.
AbstractList Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of people given these drugs do not comply with the treatment regimen prescribed. To assess the effects of compliance therapy on antipsychotic medication adherence for people with schizophrenia. Cochrane Schizophrenia Group Trials Register (June 2005). We included all randomised controlled trials of 'compliance therapy' for people with schizophrenia or related severe mental disorders. We independently extracted data and, for dichotomous data, calculated the relative risk (RR), its 95% confidence interval (CI) on an intention to treat basis. We present continuous data using the weighted mean difference statistic. We included one trial with relevant and available data (n=56, duration 2 years) comparing compliance therapy with non-specific counseling. The primary outcome 'non-compliance with treatment' showed no significant difference between compliance therapy and non-specific counseling (n=56, RR 1.23 CI 0.74 to 2.05). The compliance therapy did not substantially effect attitudes to treatment (n=50, WMD DAI score -2.10 CI -6.11 to 1.91). Very few people (~10%) left the study by one year (n=56, RR 0.5 CI 0.1 to 2.51). Mental state seemed unaffected by the therapy (n=50, WMD PANSS score 6.1 CI -4.54 to 16.74) as was insight (n=50, WMD SAI -0.5 CI -2.43 to 1.43), global functioning (n=50, WMD GAF -4.20 CI -16.42 to 8.02) and quality of life (n=50, WMD QLS -3.40 CI -16.25 to 9.45). At both one and two years the average number of days in hospital was non-significantly reduced for those allocated to the compliance therapy. There is no clear evidence to suggest that compliance therapy is beneficial for people with schizophrenia and related syndromes but more randomised studies are justified and needed in order for this intervention to be fully examined.
Author McIntosh, A M
Lawrie, S M
Conlon, L
Stanfield, A C
Author_xml – sequence: 1
  givenname: A M
  surname: McIntosh
  fullname: McIntosh, A M
  email: andrew.mcintosh@ed.ac.uk
  organization: University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK EH10 5HF. andrew.mcintosh@ed.ac.uk
– sequence: 2
  givenname: L
  surname: Conlon
  fullname: Conlon, L
– sequence: 3
  givenname: S M
  surname: Lawrie
  fullname: Lawrie, S M
– sequence: 4
  givenname: A C
  surname: Stanfield
  fullname: Stanfield, A C
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16856009$$D View this record in MEDLINE/PubMed
BookMark eNo1jstKw0AUQAdR7EN_oWThNum9N_NcSrQqFLpRcFcmkzsk0jxIdFG_3oC6OosDh7MSl13fsRAbhAwBaItSK7TKZsUDQC4lZcNXSRdiOQuXSpe_L8Rqmj5m6RDttVigtkoDuKW4K_p2ODW-C5x81jz64ZzEfkymUDff_VCP3DX-RlxFf5r49o9r8bZ7fC2e0_3h6aW436dBAlIaITdaxhBUIMBYVuA4l57JWNaV1U4pY71kNESlkeyrcmZUyDbkJhKtxea3O_-3XB2HsWn9eD7-79IPA7pCww
CitedBy_id crossref_primary_10_1002_14651858_CD007768_pub3
crossref_primary_10_1017_S1134066500005725
crossref_primary_10_1016_j_jtcc_2008_02_006
crossref_primary_10_1111_j_1447_0349_2012_00889_x
crossref_primary_10_1016_j_cpr_2016_10_009
crossref_primary_10_1016_j_ijnurstu_2008_10_010
crossref_primary_10_1002_14651858_CD004716_pub4
crossref_primary_10_2147_PPA_S349460
crossref_primary_10_1016_j_psc_2007_05_001
crossref_primary_10_1016_j_jclinepi_2008_04_005
crossref_primary_10_3109_01612840_2015_1058445
crossref_primary_10_1111_j_1447_0349_2009_00613_x
crossref_primary_10_1192_apt_14_1_79
crossref_primary_10_1007_s11920_008_0057_7
crossref_primary_10_1111_inm_12089
crossref_primary_10_1002_14651858_CD006346
crossref_primary_10_1111_j_1758_5872_2010_00067_x
crossref_primary_10_1111_jpm_12079
crossref_primary_10_1002_14651858_CD010646_pub3
crossref_primary_10_1186_s12888_016_0744_6
crossref_primary_10_1002_14651858_CD009960_pub2
crossref_primary_10_1111_j_1442_2018_2009_00440_x
crossref_primary_10_1016_j_eurpsy_2007_09_003
crossref_primary_10_1111_j_1447_0349_2009_00649_x
crossref_primary_10_1177_1078390318761790
crossref_primary_10_1016_j_mppsy_2007_07_002
crossref_primary_10_1111_j_1365_2850_2011_01809_x
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1002/14651858.CD003442.pub2
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1469-493X
ExternalDocumentID 16856009
Genre Systematic Review
Journal Article
Review
GroupedDBID ---
53G
5GY
7PX
9HA
ABJNI
ACGFO
ACGFS
AENEX
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AYR
CGR
CUY
CVF
D7G
ECM
EIF
HYE
NPM
OEC
OK1
P2P
RWY
WOW
ZYTZH
ID FETCH-LOGICAL-c4012-f03764fcc5c201fbd09e34ae278e6d8695578a4e1722b74eadb2b7f51e8c37f22
IngestDate Sat Sep 28 08:30:32 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4012-f03764fcc5c201fbd09e34ae278e6d8695578a4e1722b74eadb2b7f51e8c37f22
OpenAccessLink https://europepmc.org/articles/pmc7017223?pdf=render
PMID 16856009
ParticipantIDs pubmed_primary_16856009
PublicationCentury 2000
PublicationDate 20060719
PublicationDateYYYYMMDD 2006-07-19
PublicationDate_xml – month: 7
  year: 2006
  text: 20060719
  day: 19
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Cochrane database of systematic reviews
PublicationTitleAlternate Cochrane Database Syst Rev
PublicationYear 2006
SSID ssj0039118
Score 2.0681274
SecondaryResourceType review_article
Snippet Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of...
SourceID pubmed
SourceType Index Database
StartPage CD003442
SubjectTerms Antipsychotic Agents - therapeutic use
Confidence Intervals
Humans
Patient Compliance
Recurrence
Risk
Schizophrenia - drug therapy
Title Compliance therapy for schizophrenia
URI https://www.ncbi.nlm.nih.gov/pubmed/16856009
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NT4MwFG82TYwX4_e34bCbQaEtUI4Lm9nBedlMvC1QXrOLsGQx_vu-0jLYMqMevMDSsgb4ld97r30fhPQARZQnZKAjlnOXK8BPiinfDTKpwjxOOUt1oPBoEr28icGQDzudeve8aftXpLENsdaRs39AezUoNuBvxByPiDoef4V7UvmIV4EAJrbKeGQu2851bY00KeUc5RXca19RLdO0-riZ37nRvMd64bpczg2nNFsYZWH371eLyc_pp63VNVkvWryqit23S7StRYfItdQGhijRrHZ5XNXyrecIaxFhMqiSCdKtLG2yvvq6DLsIxEN9rZ6Ba3_AN7t4r3DyQ6FVs_jn3o3s2XVXl3RRF9LqcjKuJTVDohd11LhHH7ffkE4rawfZMD0qFWR6SA6s7eD0DehHpAPFMdkbW--IE9JrsHcs9g5i76xhf0pen4bTZOTaKhiuRNuXuspDGcCVlIFEZU1luRcD4ynQSECYizAOkHRTDqiJ0iziyAwZnlXgg5AsUpSekZ2iLOCCOAzQvg1UiAOH3EtlxgHp3peQM5qD8i_JuXm-2cKkOpnVT371bc812W8myA3ZVfgdwS3pLvOPu-ptfwFPtTkW
link.rule.ids 782
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Compliance+therapy+for+schizophrenia&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=McIntosh%2C+A+M&rft.au=Conlon%2C+L&rft.au=Lawrie%2C+S+M&rft.au=Stanfield%2C+A+C&rft.date=2006-07-19&rft.eissn=1469-493X&rft.issue=3&rft.spage=CD003442&rft_id=info:doi/10.1002%2F14651858.CD003442.pub2&rft_id=info%3Apmid%2F16856009&rft_id=info%3Apmid%2F16856009&rft.externalDocID=16856009